Compare SYBT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYBT | OCS |
|---|---|---|
| Founded | 1904 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 3 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2009 | N/A |
| Metric | SYBT | OCS |
|---|---|---|
| Price | $70.54 | $26.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $76.40 | $42.00 |
| AVG Volume (30 Days) | 162.9K | ★ 285.5K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $23,406,000.00 | N/A |
| Revenue This Year | $17.31 | $466.06 |
| Revenue Next Year | $9.32 | $479.73 |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $16.00 |
| 52 Week High | $83.83 | $30.68 |
| Indicator | SYBT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 48.52 |
| Support Level | $64.73 | $25.99 |
| Resistance Level | $71.41 | $29.19 |
| Average True Range (ATR) | 1.59 | 1.09 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 49.66 | 26.12 |
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.